DUBLIN--(BUSINESS WIRE)--The "Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Amid the COVID-19 crisis, the global market for Neurological Biomarkers for Alzheimers and Parkinsons Diseases estimated at US$4.6 Billion in the year 2020, is projected to reach a revised size of US$8.3 Billion by 2027, growing at a CAGR of 8.7% over the period 2020-2027.
The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 8.1% CAGR
The Neurological Biomarkers for Alzheimers and Parkinsons Diseases market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 8.1% over the analysis period 2020 to 2027.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.
Select Competitors (Total 46 Featured):
- AbaStar MDx
- Abbott Laboratories
- Abiant
- Acumen Pharmaceuticals
- Alseres Pharmaceuticals
- Athena Diagnostics
- Banyan Biomarkers
- Bio-Rad Laboratories
- Diagenic ASA
- Immunarray Pvt. Ltd.
- Myriad RBM
- Proteome Sciences
- ProteoSys AG
- Psynova Neurotech
- Qiagen
- Quanterix Corporation
- Thermo Fisher Scientific
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
- Total Companies Profiled: 46
For more information about this report visit https://www.researchandmarkets.com/r/jv0dk3